Eli Lilly and Company

This healthcare pharmaceutical giant and biotech stock is best known for its insulin products. But the company also develops a wide range of drugs including treatments for oncology, immunology, neurodegeneration, and cardiovascular disease. This century-old healthcare company has a loaded pipeline of medications waiting for FDA approval that could catapult your portfolio to new heights.

$711.99
(as of May 23, 9:33 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Eli Lilly and Company

Stock Price
$711.99
Ticker Symbol
LLY
Exchange
NYSE

Industry Information for Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Eli Lilly and Company

Country
USA
Full Time Employees
47,000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Fundamentals for Eli Lilly and Company

Market Capitalization
$677,889,441,792
EBITDA
$22,003,300,352
Dividends per Share
$5.40
P/E Ratio
61.54
Forward P/E Ratio
34.6
Earnings per Share
$12.27
Earnings per Share Estimate Next Year
Profit Margin
22.67%
Shares Outstanding
897,736,000
Percent Owned by Insiders
0.16%
Percent Owned by Institutions
84.14%
52-Week High
52-Week Low

Technical Indicators for Eli Lilly and Company

50-Day Moving Average
200-Day Moving Average
RSI
38.96
30.18

Analyst Ratings for Eli Lilly and Company

Strong Buy
15
Buy
7
Hold
3
Sell
1
Strong Sell
1

News About Eli Lilly and Company

May 23, 2025, 2:01 PM EST
Exploring Elfun Trusts (Trades, Portfolio)' Strategic Moves in Q1 2025 See more.
May 23, 2025, 11:13 AM EST
The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. See more.
May 23, 2025, 8:42 AM EST
For Immediate Release See more.
May 23, 2025, 3:00 AM EST
Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers. See more.